Alkylated resorcinol derivatives for the treatment of immune diseases
Patent 6274635 Issued on August 14, 2001. Estimated Expiration Date: March 22, 2020. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.
514/718, Plural oxygens514/454, Tricyclo ring system having the hetero ring as one of the cyclos514/456, Bicyclo ring system having the hetero ring as one of the cyclos (e.g., chromones, etc.)514/720, Acyclic carbon to carbon unsaturation514/730, Benzene ring containing514/731, C of C-O- group is nuclear C of a benzene ring (e.g., phenol, phenolate, etc.)568/626, Benzene ring containing568/630, Ether oxygen bonded directly to benzene ring568/648, Polyoxy568/650, Hydroxy bonded directly to the benzene ring (H of -OH may be replaced by a Group IA or IIA light metal)568/651, Plural ether oxygens bonded directly to the benzene ring568/652, Ether oxygen is ortho to the hydroxy568/658, Acyclic hydrocarbyl group bonded directly to the benzene ring568/662, Polyoxy568/716Phenols (H of -OH may be replaced by a Group IA or IIA light metal)
The present invention provides a method, compounds, and compositions for treating a disease associated with immune dysfunction. In accordance with the method, a pharmacologically-acceptable composition including at least one compound selected from the group of compounds consisting of 5-alkyl-resorcinol derivatives, cannabinol derivatives, cannabidiol derivatives, cannabigerol derivatives, and combinations thereof is administered to a patient under conditions sufficient to attenuate the dysfunction within the immune system. The invention also provides an antiviral cannabinol derivative that can be used in the inventive method. The invention also provides an alkylated resorcinol derivative and a method of using the alkylated resorcinol derivative to attenuate the growth of a neoplasm. The method and compound are useful for treating diseases of the immune system, such as HIV disease and neoplastic disorders.
Other References
Pospisil et al., Eur. Polym. J. 6(10), 1970, pp. 1347-1358 (Abstract Only).
Pospisil et al., Fette, Seifen, Anstrichm., 70(6), 1968, pp. 442-445 (Abstract Only).
Abrams, J. of Acq. Immun. Def. Syn. , 25:74-80 (2000)
Baek, Seung, et al., Arch. Pharmacal Res., 19:228-230 (1996)
Beutler, J. Nat. Prod., 61: 1509-1512 (1998)
Bhargava, General Pharmacology, 9:195-213 (1978)
Burstein, et al., Biochemical Pharm., 29:2153-2154 (1980)
Cabral, et al., Adv. Biosci. 80: 93-105 (1991)
Carchman, et al., Marihuana: Chem., Biochem., Cell. Eff., Proc. Satell. Symp., (1976), 329-345 (1975)
Elkin, . et al., Abstract, Delta-9 Tetrahydrocannabinol a novel treatment for inflammatory demyelination, Experimental Biology, Annual meeting, Apr. 29 (1987)
Gallily, et al., J. Pharmacol. Exp. Ther., 283:918-924 (1997)
Kawakami, et al., Int. J. Immunopharmacol., 10:485-488 (1988)
Mahadevan, et al., J. Med. Chem. 43:3778-3785 (2000)
Singh, Sheo et al., J. Org. Chem. 61:7727-7727 (1996)
Spector, et al., Marijuana and Immunosuppression in Man, Watson, R.R. (ED.). Drugs of Abuse and Immune Function. IX+237P. CRC, 1990 73-86
Spector, et al., FASEB 4:A1021 (1990)
Timpone, et al., Aids Res. Hum. Retroviruses, 13:305-315 (1997)
Trinkl, press release of Jul. 13, 2000 published on World Wide Web at http://www.ucsf.edu/pressrel/2000/07/071302.html and entitled "Marijuana does not appear to alter viral loads of HIV Patients taking Protease Inhibitors"
Waksman, J. of Autoimmunity, suppl. 56 (1999)
Watzl, et al., Adv. Exp. Med. Biol., 288:63-70 (1991)
Watzl, et al., Int. J. Immunopharmacol., 13:1091-1097 (1991)
Zheng, et al., Int. J. Immunopharmacol., 14:1445-1452 (1992)
Baek, Seng HWA et al., Boron trifluoride etherate on silica-A modified Lewis acid reagent (VII). Antitumor Activity of Cannabigerol against Human Oral Epitheloid Carcinoma Cells, Arch. Pharm. Res. vol. 21, No. 3, pp. 353-356 (1998)
Database WPI, Sec. Ch, Wk 200050, Derwent Publications Ltd, AN 2000-545825, XP002151974 & JP 2000 191520 A (SAKUMA K), (Jul. 11, 2000) Abstract
Harris, et al., Structure-Antitumor Activity of Cannabinoids, Pharm., vol. 17, No. 2, 1975, p. 265, XP000957659, Abstract
Harris et al., Anti Tumor Properties of Cannabinoids, Pharm. Of Marihuana, pp. 749-762, (1976)
Hartmann et al., Antiestrogens. Synthesis and Evaluation of Mammary Tumor Inhibiting Activity of 1,1, 2,2-Tetraalkyl1-1,2-diphenylethanes, J. Med. Chem. (1980), 23, 841-848
Lyman et al., Delta 9-tetrahydrocannabinol: A Novel Treatment for Experimental Autoimmune Encephalomyelitis, J. Neuroimmunol., 23 (1989) 73-81, Abstract
Nahas et al., Inhibitor effect of 5-amylresorcinol on lymphoblastic tranformation, C.R. Hebd. Seances Acad. Sci., Ser. D (1974) (and English translation)
Nichols et al., Allyl Benzene Analogs of Delta-9 Tetra Hydro Cannabinol as Tumor Growth Inhibitors Life Sci., 21, No. 9, (1977), pp. 1245-1248
Adams et al., 70, J. Med. Chem., 662-68 (1947)
Adams et al., 71, J. Med. Chem., 1624-28 (1949)
Baeuerle et al., 2, Ann. Rev. Immunol., 12, 141-79 (1994)
Biswas, et al., J. of Acq. Immun. Def. Syn. and Hum. Retrovirol., 18, 426-34 (1998)
Brenneisen, et al. Int. J. of Clin. Pharmacol. Ther., 34, 446-52 (1996)
Bornheim, Abstract, Cannabidiol-Effect on Cytochro P450 Isozymes, NIH Grant No. 5R01DA04265-13
Bornheim, Chem. Res. Toxicol., 11, 1209-16 (1998)
Brenneisen, et al., Int. J. of Clin. Pharm. Ther., 34, 446-52 (1996)
Burstein, et al., Pharmacol Ther., 82, 87-96 (1999)
Burstein, et al, J. of Pharm. Exp. Ther., 251, 531-35 (1989)
Busch-Petersen, et al., J. Med. Chem., 39, 3790-96 (1996)
Charalambous, et al., Pharm Biochem. Behav, 40, 509-12 (1991)
Daaka, et al., DNA Cell Biol., 16, 301-09 (1997)
Desoize, Anticancer Res., 14, 2291-94 (1994)
Dewhirst, Prostaglandins, 20, 209-22 (1980)
Di Franco, AEP, 6, 283-89 (1996)
Dol, et al., Eur. J. Org. Chem., 359-64 (1998)
Dominianni, et al., J. Org. Chem., 42, 344-46 (1977)
Dumais, et al., J Biol Chem., 42, 27306-14 (1998)
Felder, et al., Mol. Pharmcol., 42, 838-45 (1992)
Formukong, et al., J. Pharm. Pharmacol., 41, 705-09 (1989)
Furstner, et al., J. Org. Chem., 62, 2332-36 (1997)
Princ. Med. Chemistry, pp. 246-298, Foye et al., eds., Fourth Edition (Williams & Wilkins 1995)
Evans et al., Biochem. Pharm., 36, 2035-37 (1987)
Galve-Roperh, et al., Nat. Med., 6, 313-19 (2000)
Gareau, et al., Bioorg. Med. Chem. Let., 6,189-94 (1996)
Gervaix, et al., Proc. Natl. Acad. Sci. (U.S.A.), 94, 4653-58 (1997)
Gollapudi, et al., Acids Res. Hum. Retrovir., 14, 499-504 (1998)
Gorter, et al., Cannabis in der Behandlung krebskrander and HIV-positiver Patienten Die erste klinische Cannabis-Studie in Deutschland, Brohanf Symposium, 691-92 (1997) (with translation)
Granelli-Piperno, et al., Proc. Natl. Acad. Sci. (U.S.A.), 92, 10944-48 (1995)
Griffin, et al., Br. J. Pharmacol., 126, 1575-84, (1999)
Groul, Abstract, Drug Effects on Neuronal Development in Pediatric Aids, NIH Grant No. 1R01DA10187-01A2
Gurwitz, et al., Molecular Medicine Today, 196-200 (1998)
Harvey, et al., Biomed. Mass Spect., 4, 364-70 (1977)
Herring, et al., Biochem. Pharmacol., 55, 1013-23 (1998)
Hladyszowski, et al., Free Rad. Res., 28, 359-68 (1997)
Huffman, et al., Bioorg Med. Chem., 6, 2281-88 (1998)
Huffman, et al., Life Sci., 56, 2021-24 (1995)
Huffman, Abstract, Synthesis of Cannabinoids Analogues and Metabolites, NIH Grant No. 5R01DA03590-11
Huffman, et al., Bioor. Med. Chem., 6, 2383-96 (1998)
Huffman, et al., J. Med Chem., 39, 3875-77 (1996)
Consequences of Marijuana Use and Abuse, in "Marijuana and Medicine", 115-21, Joy et al., eds. (National Academy Press, 1999)
Kaminski, J. Neuroimmunol., 83, 124-32 (1998)
Kaminski, Toxicol. Let., 102-103, 59-63 (1998)
Klein, et al., J. Neuroimmunol., 83, 102-15 (1998)
Koch, et al. Synthesis of 5-Alkylresorcinols, (Unclassified Report) (1962)
Kozubek, et al., Chem. Rev., 99, 1-25 (1999)
Lancz, et al., Proc. Soc. Exp. Biol. Med., 4, 401-04 (1991)
Lemberger, et al., Clin. Pharmacol. Ther., 18, 720-26 (1975)
Liddle, et al., Bioorg Med. Chem. Let., 8, 2223-26 (1998)
Loev, et al., J. Med. Chem., 16, 1200-06 (1973)
Loev, et al., J. Med. Chem., 11, 1234-35 (1974)
Lytollis, et al., J. Am. Chem. Soc., 117, 12683-90 (1995)
Madani, et al., Proc. Natl. Acad. Sci. (U.S.A.), 95, 8005-10 (1998)
Makriyannis, et al., Life Sci., 47, 2173-84 (1990)
Martin, et al., Pharm. Biochem. Behav., 46, 295-301 (1993)
Matsuyama, et al., ADS, 5, 1405-17 (1991)
McFerling, Chicago Tribune, Dec. 18 (1998)
McPartland, et al., Alt. Ther., 5, 57-62 (1999)
Mishkin, et al., Proc. Soc Exp. Biol Med., 185, 41-48 (1987)
Mon, et al., Biochem. Pharmacol., 30, 31-43 (1981)
Mon, et al., Biochem. Pharmacol., 30, 45-58 (1981)
Morse, et al., Life Sci ., 56, 1957-62 (1995)
Nahas, et al., Fed. Pro., 36, 1748-52 (1977)
Bennett, et al., pp. 717-721 in Marihuana and Medicine, Nahas, et al., eds. (Humana Press 1999)
Noe, et al., Chapter 25 in "Drugs of Abuse, Immunolodulation, and Aids," Friedman et al. Eds. pp. 223-224 (Plenum Press, 1998)
Noe, et al., Advances in Experimental Medicine and Biology, 437, 223-29 (1998)
Novak, et al., Tetrahedron Let., 253-54 (1982)
Ongradi, et al., Pathol Oncol Res., 4, 191-199 (1998)
Papahatjis, et al., J. Med. Chem., 1195-200 (1998)
Pars, et al., J. Med. Chem, 19, 455-53
Pate, J. Int. Hemp. Assoc., 2, 74-76 (1995)
Pertwee, Pharmacol, Ther., 74, 129-80 (1997)
Petitet, et al., Life Sci., 63, PL 1-6 (1998)
Pillai, et al. Arch Toxicol, 65, 609-617 (1991)
Piomelli, Nat. Med., 6, 255-56 (2000)
Pop, Cur. Op. Chem. Biol., 3, 418-25 (1999)
Razdan, Abstract, Synthesis of Tetrahydrocannabino/related compounds, NIH Grant 5R01DA05488-12
Razdan, et al., J. Med. Chem., 19, 454-60 (1976)
Razdan, Pharmacolog Rev. 38, 75-148 (1986)
Del Real, et al., AIDS, 12, 865-72 (1998)
Reggio, et al., Life Sci., 56, 2025-32 (1995)
Reggio, et al., J. Med. Chem., 20, 3312-18 (1997)
Rhee, et al., J. Med. Chem., 40, 3228-33 (1997)
Rhee, et al., J. Neurochem. 71, 1525-34 (1998)
Ross, et al., Br. J. Pharmacol., 126, 665-72 (1999)
Scannell, et al., J. Am. Chem. Soc., 110, 3651-53 (1988)
Seltzman, Cur. Med. Chem., 6, 685-704 (1999)
Showalter, et al., J. Pharm. Exp. Ther., 278, 989-99 (1996)
Sidney, et al., Amer. Journal of Public Health, 87, 585-90 (1997)
Singh, et al., J. Am. Chem. Soc., 117, 12691-99 (1995)
Specter, Cannabinoids and Immunity to Viruses, 131-34 (1996)
Spira, et al., J. Exp. Med., 183, 215-25 (1996)
Sproncn et al, Biochem. Pharm., 27, 607-08 (1978)
Srivastava, et al., Immunopharmocology, 40, 179-85 (1998)
Tao, et al., Mol. Pharmacol., 55, 605-13 (1999)
The Herald, HIV rebounds when pills cut back, Oct. 29, 12A (1998)
Thomas, et al., J. Pharmacol. Exp. Ther., 255, 624-30 (1990)
Thomas, et al., J. Pharmacol. Exp. Ther., 285, 285-92 (1998)
Thomas, et al., Mol. Pharmacol., 40, 656-65 (1991)
March 22, 2020. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.
